Cathie Wood Dumps Another $3 Million In AMD Stock As Ark Invest Trims For Third Day Running, This Is the AI Stock She Is Buying InsteadMay 10, 2026
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
On Thursday, Cathie Wood-led Ark Invest made notable trades involving Advanced Micro Devices Inc. and Tempus AI Inc.. These trades reflect Ark’s strategic repositioning amid evolving market dynamics.
The AMD Trade
ARK Innovation ETF fund reduced its stake in Advanced Micro Devices Inc. by selling 8,045 shares. The transaction, valued at approximately $3.3 million, was executed at AMD’s closing price of $408.46 on Thursday.
This move aligns with Ark’s recent trend of trimming its AMD holdings. Recently, AMD’s CEO, Lisa Su, highlighted the company’s strong start to 2026, driven by increased AI adoption and demand for compute infrastructure. The rise of AI agents has significantly boosted the need for CPUs, despite the critical role of GPUs in AI acceleration.
Don't Miss:
A single bad hire can set a startup back years. Here are the 5 hires founders most often misjudge — and why Still Learning the Market? These 50 Must-Know Terms Can Help You Catch Up Fast
Despite the positive outlook, Ark’s decision to sell AMD shares may indicate a strategic shift. The company has been capitalizing on AMD’s recent performance, as the stock has been hot due to the AI-driven demand surge. On Tuesday, Ark sold $16 million worth of AMD shares, while on Wednesday the firm offloaded stock worth $8 million. AMD stock has shot up over 16% in the last 5 days
The Tempus AI Trade
In contrast, Ark Invest increased its position in Tempus AI Inc. by acquiring a total of 154,045 shares across its ARK Genomic Revolution ETF and ARKK funds. The purchase, valued at approximately $7.7 million, was made at Tempus AI’s closing price of $49.47.
Tempus AI recently reported a 36.1% rise in first-quarter revenue, driven by strong demand for its oncology diagnostics and AI-driven data business. The company exceeded analyst expectations with quarterly revenue reaching $348.1 million. Despite widening net losses, Tempus AI raised its full-year revenue outlook, signaling confidence in its growth trajectory.
See Also: Avoid the #1 Investing Mistake: How Your ‘Safe' Holdings Could Be Costing You Big Time
This strategic investment by Ark reflects confidence in Tempus AI’s potential, particularly given its impressive revenue growth and market position. The company’s diagnostics revenue saw a 34.7% increase, while its data and applications revenue climbed 40.5% to $87 million, underscoring its robust performance in the AI sector.
Story Continues
Ark purchased $7.8 million worth of Tempus AI stock on Thursday.
Other Key Trades:
Sold 44,291 shares of CareDx Inc. (CDNA) from ARKG. Sold 33,134 shares of Adaptive Biotechnologies Corp. (ADPT) from ARKG. Bought 102,247 shares of Intellia Therapeutics Inc. (NTLA) in ARKK. Sold 9,210 shares of Teradyne Inc. (TER) from ARKK.
Photo: Ira Lichi / Shutterstock
Read Next:
Skip the Regrets: The Essential Retirement Tips Experts Wish Everyone Knew Earlier. Thinking about ETFs? See what investment risks you should be aware of before you buy.
Building Wealth Across More Than Just the Market
Building a resilient portfolio means thinking beyond a single asset or market trend. Economic cycles shift, sectors rise and fall, and no one investment performs well in every environment. That's why many investors look to diversify with platforms that provide access to real estate, fixed-income opportunities, professional financial guidance, precious metals, and even self-directed retirement accounts. By spreading exposure across multiple asset classes, it becomes easier to manage risk, capture steady returns, and create long-term wealth that isn't tied to the fortunes of just one company or industry.
Connect Invest
Connect Invest is a real estate investment platform that allows investors to access short-term, fixed-income opportunities backed by a diversified portfolio of residential and commercial real estate loans. Through its Short Notes structure, investors can choose defined terms (6, 12, or 24 months) and earn monthly interest payments while gaining exposure to real estate as an asset class. For investors focused on diversification, Connect Invest may serve as one component within a broader portfolio that also includes traditional equities, fixed income, and other alternative assets—helping balance exposure across different risk and return profiles.
Mode Mobile
Mode Mobile is changing the way people interact with their phones by letting users earn money from the same apps and activities they already use every day. Instead of platforms keeping all the advertising revenue, Mode Mobile shares a portion back with users who engage with content, play games, and scroll on their devices. Named one of Deloitte's fastest-growing software companies in North America, the company has built a large beta user base and is scaling a model that turns everyday smartphone usage into a potential income stream. For investors, Mode Mobile offers exposure to the expanding mobile advertising and attention economy through a pre-IPO opportunity tied to a new approach to user monetization.
rHealth
rHealth is building a space-tested diagnostics platform designed to bring lab-quality blood testing closer to patients in minutes rather than weeks. Originally validated in collaboration with NASA for use aboard the International Space Station, the technology is now being adapted for at-home and point-of-care settings to address widespread delays in diagnostic access.
Backed by institutions including NASA and the NIH, rHealth is targeting the large global diagnostics market with a multi-test platform and a model built around devices, consumables, and software. With FDA registration in progress, the company is positioning itself as a potential shift toward faster, more decentralized healthcare testing.
Direxion
Direxion specializes in leveraged and inverse ETFs designed to help active traders express short-term market views during periods of volatility and major market events. Rather than long-term investing, these products are built for tactical use—allowing investors to take magnified bullish or bearish positions across indices, sectors, and single stocks. For experienced traders, Direxion offers a way to respond quickly to changing market conditions and act on high-conviction views with greater flexibility.
Immersed
Immersed is a spatial computing company building immersive productivity software that enables users to work across multiple virtual screens inside VR and mixed-reality environments. Its platform is used by remote workers and enterprises to create virtual workspaces that reduce reliance on traditional physical hardware while improving focus and collaboration. The company is also developing its own lightweight VR headset and AI productivity tools, positioning itself in the future-of-work and spatial computing space. Through its pre-IPO offering, Immersed is opening access to early-stage investors looking to diversify beyond traditional assets and gain exposure to emerging technologies shaping how people work.
Arrived
Backed by Jeff Bezos, Arrived Homes makes real estate investing accessible with a low barrier to entry. Investors can buy fractional shares of single-family rentals and vacation homes starting with as little as $100. This allows everyday investors to diversify into real estate, collect rental income, and build long-term wealth without needing to manage properties directly.
Masterworks
Masterworks enables investors to diversify into blue-chip art, an alternative asset class with historically low correlation to stocks and bonds. Through fractional ownership of museum-quality works by artists like Banksy, Basquiat, and Picasso, investors gain access without the high costs or complexities of owning art outright. With hundreds of offerings and strong historical exits on select works, Masterworks adds a scarce, globally traded asset to portfolios seeking long-term diversification.
Public
Public is a multi-asset investing platform built for long-term investors who want more control, transparency, and innovation in how they grow wealth. Founded in 2019 as the first broker-dealer to offer commission-free, real-time fractional investing, Public now lets users invest in stocks, bonds, options, crypto, and more—all in one place. Its latest feature, Generated Assets, uses AI to turn a single idea into a fully customized, investable index that can be explained and backtested before committing capital. Combined with AI-powered research tools, clear explanations of market moves, and an uncapped 1% match for transferring an existing portfolio, Public positions itself as a modern platform designed to help serious investors make more informed decisions with context.
AdviserMatch
AdviserMatch is a free online tool that helps individuals connect with financial advisors based on their goals, financial situation, and investment needs. Instead of spending hours researching advisors on your own, the platform asks a few quick questions and matches you with professionals who can assist with areas like retirement planning, investment strategy, and overall financial guidance. Consultations are no-obligation, and services vary by advisor, giving investors a chance to explore whether professional advice could help improve their long-term financial plan.
Accredited Debt Relief
Accredited Debt Relief is a debt consolidation company focused on helping consumers reduce and manage unsecured debt through structured programs and personalized solutions. Having supported more than 1 million clients and helped resolve over $3 billion in debt, the company operates within the growing consumer debt relief industry, where demand continues to rise alongside record household debt levels. Its process includes a quick qualification survey, personalized program matching, and ongoing support, with eligible clients potentially reducing monthly payments by 40% or more. With industry recognition, an A+ BBB rating, and multiple customer service awards, Accredited Debt Relief positions itself as a data-driven, client-focused option for individuals seeking a more manageable path toward becoming debt-free.
Finance Advisors
Finance Advisors helps Americans approach retirement with greater clarity by connecting them to vetted, fiduciary financial advisors who specialize in tax-aware retirement planning. Rather than focusing on products or investment performance alone, the platform emphasizes strategies that account for after-tax income, withdrawal sequencing, and long-term tax efficiency—factors that can materially impact retirement outcomes. Free to use, Finance Advisors gives individuals with meaningful savings access to a level of planning sophistication historically reserved for high-net-worth households, helping reduce hidden tax risk and improve long-term financial confidence.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
View Comments
Adaptive Biotechnologies Reports First Quarter 2026 Financial ResultsMay 5, 2026
Adaptive Biotechnologies
SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2026.
“We delivered strong first quarter results based on accelerating adoption of MRD across both clinical testing and drug development. Our performance reinforces our market leadership position and the differentiated value of our platform,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “With disciplined execution and multiple growth drivers in place, we are well positioned to sustain our growth trajectory and create long-term value.”
Recent Highlights
Revenue for the first quarter of 2026 was $70.9 million. The MRD business, which contributed 95% of revenue, grew 53% versus the first quarter of 2025. clonoSEQ® test volume in the first quarter of 2026 increased 41% to 32,595 tests delivered versus the first quarter of 2025. Recognized $9.0 million in MRD pharma regulatory milestone revenue, the first U.S. primary endpoint milestone. Raising full year 2026 MRD revenue guidance to a new range of $260 million to $270 million, implying annual growth of 22% to 27%.
First Quarter 2026 Financial Results
Revenue was $70.9 million for the quarter ended March 31, 2026, representing a 35% increase from the first quarter in the prior year. Excluding revenue recognized under the Genentech Agreement, which did not generate revenue in the quarter ended March 31, 2026, revenue for the current quarter increased 45% from the first quarter in the prior year. MRD revenue was $67.1 million for the quarter, representing a 53% increase from the first quarter in the prior year. Immune Medicine revenue was $3.8 million for the quarter, representing a 57% decrease from the first quarter in the prior year. Excluding revenue from the Genentech Agreement, Immune Medicine revenue for the quarter ended March 31, 2026 decreased 26% from the first quarter in the prior year.
Operating expenses for the first quarter of 2026 were $90.1 million, compared to $82.0 million in the first quarter of the prior year, representing an increase of 10%.
Interest and other income, net was $2.1 million for the first quarter of 2026, compared to $2.7 million in the first quarter of the prior year. Interest expense from our revenue interest purchase agreement was $2.9 million in both the first quarter of 2026 and the first quarter of the prior year.
Story Continues
Net loss was $20.0 million for the first quarter of 2026, compared to $29.8 million for the same period in 2025. Excluding revenue generated from the Genentech Agreement, net loss was $33.4 million for the first quarter of 2025.
Adjusted EBITDA (non-GAAP) was a loss of $2.5 million for the first quarter of 2026, compared to a loss of $12.7 million for the first quarter of the prior year. Excluding revenue generated from the Genentech Agreement, Adjusted EBITDA was a loss of $16.3 million for the first quarter of 2025.
Cash, cash equivalents and marketable securities was 237.2 million as of March 31, 2026, inclusive of $15.3 million of cash and cash equivalents held by Digital Biotechnologies, Inc.
2026 Updated Financial Guidance
Adaptive Biotechnologies expects full year revenue for the MRD business to be between $260 million and $270 million, updated from the previous range between $255 million and $265 million. No revenue guidance is provided for the Immune Medicine business.
We expect full year total company operating expenses, including cost of revenue, to be between $350 million and $360 million.
Management will provide further details on the outlook during the conference call.
Webcast and Conference Call Information
Adaptive Biotechnologies will host a conference call to discuss its first quarter 2026 financial results after market close on Tuesday, May 5, 2026 at 4:30 PM Eastern Time. The conference call can be accessed at http://investors.adaptivebiotech.com. The webcast will be archived and available for replay at least 90 days after the event.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
Use of Non-GAAP Financial Measure
To supplement our unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), this press release also includes references to Adjusted EBITDA, which is a non-GAAP financial measure that we define as net loss attributable to Adaptive Biotechnologies Corporation adjusted for interest and other income, net, interest expense, income tax (expense) benefit, depreciation and amortization expense, impairment costs for long-lived assets, restructuring expense and share-based compensation expense. We define our segment Adjusted EBITDA in the same way to the extent the net loss attributable to Adaptive Biotechnologies Corporation and adjustments are allocable to each segment. We have provided reconciliations of net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this press release.
Management uses Adjusted EBITDA, including segment Adjusted EBITDA, to evaluate the financial performance of our business and segments and to evaluate the effectiveness of our strategies. We present these figures because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance.
Adjusted EBITDA, including segment Adjusted EBITDA, has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments we make. In particular, we expect to incur meaningful share-based compensation expense in the future. Other limitations include that Adjusted EBITDA, including segment Adjusted EBITDA, does not reflect:
all expenditures or future requirements for capital expenditures or contractual commitments; changes in our working capital needs; interest expense, which is an ongoing element of our costs to operate; income tax (expense) benefit, which may be a necessary element of our costs and ability to operate; the costs of replacing the assets being depreciated and amortized, which will often have to be replaced in the future; the noncash component of employee compensation expense; long-lived assets impairment costs; and the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations, such as our restructuring activities and reductions in workforce.
In addition, Adjusted EBITDA, including segment Adjusted EBITDA, may not be comparable to similarly titled measures used by other companies in our industry or across different industries.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
Adaptive Biotechnologies Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
(unaudited) Three Months Ended March 31, 2026 2025 Revenue $ 70,874 $ 52,443 Operating expenses Cost of revenue 18,708 16,979 Research and development 23,623 24,203 Sales and marketing 26,346 23,047 General and administrative 20,984 17,399 Amortization of intangible assets 419 419 Total operating expenses 90,080 82,047 Loss from operations (19,206 ) (29,604 ) Interest and other income, net 2,080 2,679 Interest expense (2,889 ) (2,905 ) Net loss (20,015 ) (29,830 ) Add: Net income attributable to noncontrolling interest (18 ) (22 ) Net loss attributable to Adaptive Biotechnologies Corporation $ (20,033 ) $ (29,852 ) Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted $ (0.13 ) $ (0.20 ) Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted 155,521,048 149,195,028
Adaptive Biotechnologies Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts) March 31, 2026 December 31, 2025 (unaudited) Assets Current assets Cash and cash equivalents $ 77,581 $ 70,495 Short-term marketable securities (amortized cost of $140,762 and $156,246, respectively) 140,753 156,485 Accounts receivable, net 48,315 50,365 Inventory 11,206 9,820 Prepaid expenses and other current assets 13,952 13,020 Total current assets 291,807 300,185 Long-term assets Property and equipment, net 30,774 34,107 Operating lease right-of-use assets 40,248 40,616 Long-term marketable securities (amortized cost of $18,908 and $13,220, respectively) 18,889 13,234 Restricted cash 2,709 2,689 Intangible assets, net 1,307 1,726 Goodwill 118,972 118,972 Other assets 1,237 1,207 Total assets $ 505,943 $ 512,736 Liabilities and shareholders’ equity Current liabilities Accounts payable $ 9,615 $ 6,467 Accrued liabilities 7,465 7,700 Accrued compensation and benefits 6,217 16,992 Current portion of operating lease liabilities 8,513 8,920 Current portion of deferred revenue 49,397 45,194 Current portion of revenue interest liability, net 5,804 4,642 Total current liabilities 87,011 89,915 Long-term liabilities Operating lease liabilities, less current portion 69,115 70,228 Deferred revenue, less current portion 807 1,006 Revenue interest liability, net, less current portion 124,749 126,566 Other long-term liabilities 20 20 Total liabilities 281,702 287,735 Commitments and contingencies Shareholders’ equity Preferred stock: $0.0001 par value, 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025 — — Common stock: $0.0001 par value, 340,000,000 shares authorized at March 31, 2026 and December 31, 2025; 159,697,221 and 153,779,418 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively 16 15 Additional paid-in capital 1,599,708 1,581,848 Accumulated other comprehensive (loss) gain (28 ) 253 Accumulated deficit (1,383,356 ) (1,363,323 ) Total Adaptive Biotechnologies Corporation shareholders’ equity 216,340 218,793 Noncontrolling interest 7,901 6,208 Total shareholders’ equity 224,241 225,001 Total liabilities and shareholders’ equity $ 505,943 $ 512,736
Adjusted EBITDA
The following is a reconciliation of net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, to Adjusted EBITDA for the periods presented (in thousands, unaudited):
Three Months Ended March 31, 2026 2025 Net loss attributable to Adaptive Biotechnologies Corporation $ (20,033 ) $ (29,852 ) Interest and other income, net (2,080 ) (2,679 ) Interest expense 2,889 2,905 Depreciation and amortization expense 3,837 4,731 Impairment of long-lived assets 347 — Restructuring expense 643 — Share-based compensation expense 11,928 12,147 Adjusted EBITDA $ (2,469 ) $ (12,748 )
Segment Information (Including Segment Adjusted EBITDA)
The following sets forth segment information for the periods presented (in thousands, unaudited):
Three Months Ended March 31, 2026 2025 MRD: Revenue $ 67,093 $ 43,721 Adjusted EBITDA 12,138 (4,111 ) Reconciliation of Net Income (Loss) to Adjusted EBITDA: Net income (loss) $ 3,362 $ (12,238 ) Depreciation and amortization expense 2,381 2,663 Impairment of long-lived assets — — Restructuring expense 248 — Share-based compensation expense 6,147 5,464 Adjusted EBITDA $ 12,138 $ (4,111 ) Immune Medicine(1): Revenue $ 3,781 $ 8,722 Adjusted EBITDA (10,360 ) (5,106 ) Reconciliation of Net Loss to Adjusted EBITDA: Net loss $ (15,929 ) $ (10,919 ) Depreciation and amortization expense 1,005 1,623 Impairment of long-lived assets 347 — Restructuring expense 395 — Share-based compensation expense 3,822 4,190 Adjusted EBITDA $ (10,360 ) $ (5,106 )
(1) Expenses related to Digital Biotechnologies, Inc. are no longer included in the Immune Medicine segment.
View Comments
